|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
JPS6147500A
(ja)
|
1984-08-15 |
1986-03-07 |
Res Dev Corp Of Japan |
キメラモノクロ−ナル抗体及びその製造法
|
|
EP0173494A3
(en)
|
1984-08-27 |
1987-11-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric receptors by dna splicing and expression
|
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
|
JPS61134325A
(ja)
|
1984-12-04 |
1986-06-21 |
Teijin Ltd |
ハイブリツド抗体遺伝子の発現方法
|
|
EP0247091B1
(en)
|
1985-11-01 |
1993-09-29 |
Xoma Corporation |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5221618A
(en)
|
1987-11-24 |
1993-06-22 |
Connaught Laboratories Limited |
Genetic detoxification of pertussis toxin
|
|
US5332583A
(en)
|
1987-11-24 |
1994-07-26 |
Connaught Laboratories Limited |
Vaccine containing genetically-detoxified pertussis holotoxin
|
|
US5244657A
(en)
|
1987-11-24 |
1993-09-14 |
Connaught Laboratories Limited |
Genetic detoxification of pertussis toxin
|
|
GB8727489D0
(en)
|
1987-11-24 |
1987-12-23 |
Connaught Lab |
Detoxification of pertussis toxin
|
|
US5358868A
(en)
|
1987-11-24 |
1994-10-25 |
Connaught Laboratories Limited |
Genetic detoxification of pertussis toxin
|
|
NZ230747A
(en)
|
1988-09-30 |
1992-05-26 |
Bror Morein |
Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5736139A
(en)
*
|
1989-10-31 |
1998-04-07 |
Ochidian Pharmaceuticals, Inc. |
Treatment of Clostridium difficile induced disease
|
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
|
US5231003A
(en)
|
1990-05-11 |
1993-07-27 |
Cambridge Bioscience Corporation |
Monoclonal antibodies specific for toxin b of clostridium difficile
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
US5283185A
(en)
|
1991-08-28 |
1994-02-01 |
University Of Tennessee Research Corporation |
Method for delivering nucleic acids into cells
|
|
US5908635A
(en)
|
1994-08-05 |
1999-06-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method for the liposomal delivery of nucleic acids
|
|
AUPM873294A0
(en)
|
1994-10-12 |
1994-11-03 |
Csl Limited |
Saponin preparations and use thereof in iscoms
|
|
US6096716A
(en)
|
1994-12-12 |
2000-08-01 |
The Board Of Regents, The University Of Texas System |
Liposome-mediated transfection of central nervous system cells
|
|
AUPO517897A0
(en)
|
1997-02-19 |
1997-04-11 |
Csl Limited |
Chelating immunostimulating complexes
|
|
DE19739685A1
(de)
*
|
1997-09-10 |
1999-03-11 |
Eichel Streiber Christoph Von |
Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
|
|
AUPP807399A0
(en)
|
1999-01-08 |
1999-02-04 |
Csl Limited |
Improved immunogenic lhrh composition and methods relating thereto
|
|
ES2572834T3
(es)
|
1999-02-17 |
2016-06-02 |
Csl Limited |
Complejos inmunogénicos y métodos relacionados con los mismos
|
|
US20040126829A1
(en)
|
2001-12-18 |
2004-07-01 |
Hildebrand William H. |
Anti-HLA assay and methods
|
|
GB0309126D0
(en)
|
2003-04-17 |
2003-05-28 |
Neutec Pharma Plc |
Clostridium difficile focussed antibodies
|
|
EP2857418B1
(en)
|
2004-02-06 |
2017-07-26 |
University of Massachusetts |
Antibodies against Clostridium difficile toxins and uses thereof
|
|
CA2572427A1
(en)
|
2004-07-18 |
2006-01-18 |
Heather L. Davis |
Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
|
|
AU2005333126A1
(en)
|
2004-07-18 |
2006-12-21 |
Csl Limited |
Methods and compositions for inducing innate immune responses
|
|
EP1799262A4
(en)
*
|
2004-10-15 |
2009-10-21 |
Seattle Genetics Inc |
ANTI-CD70 ANTIBODIES AND ITS USE FOR THE TREATMENT AND PREVENTION OF CANCER DISORDERS AND IMMUNE DISORDERS
|
|
EP1833510A4
(en)
|
2004-12-27 |
2010-02-10 |
Progenics Pharmaceuticals Neva |
ORAL ADMINISTRATION ANTITOXIN ANTIBODIES AND METHODS OF MAKING AND USING THE SAME
|
|
US7790203B2
(en)
|
2005-12-13 |
2010-09-07 |
Lowder Tom R |
Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions
|
|
NZ596295A
(en)
*
|
2006-03-10 |
2013-01-25 |
Wyeth Corp |
Anti-5T4 antibodies and uses thereof
|
|
EP2097097B1
(en)
|
2006-12-01 |
2018-05-30 |
E. R. Squibb & Sons, L.L.C. |
Antibodies, in particular human antibodies, that bind cd22 and uses thereof
|
|
US7597891B2
(en)
|
2006-12-13 |
2009-10-06 |
Simon Michael R |
Synthesis of human secretory IgA for the treatment of Clostridium difficile associated diseases
|
|
JPWO2008114733A1
(ja)
*
|
2007-03-16 |
2010-07-01 |
協和発酵キリン株式会社 |
抗Ｃｌａｕｄｉｎ−４抗体
|
|
MX2010005282A
(es)
*
|
2007-11-13 |
2010-08-31 |
Teva Pharma |
Anticuerpos humanizados contra tl1a.
|
|
US9274119B2
(en)
|
2008-01-11 |
2016-03-01 |
The University Of Tokyo |
Anti-CLDN6 antibody
|
|
US7740844B2
(en)
*
|
2008-04-29 |
2010-06-22 |
Taiwan Liposome Co. Ltd |
Anti-VEGF monoclonal antibody
|
|
GB0921288D0
(en)
|
2009-12-04 |
2010-01-20 |
Health Prot Agency |
Therapies for preventing or suppressing clostridium difficile infection
|
|
BR112012026021B1
(pt)
|
2010-04-15 |
2022-05-03 |
Progenics Pharmaceuticals, Inc |
Anticorpos, seus fragmentos de ligação ao antígeno e seus usos, composições e uso das mesmas, linhagem de células de hibridoma, kit, ácido nucleico, e vetor de expressão
|
|
BR112014004162A2
(pt)
*
|
2011-08-22 |
2018-04-24 |
Cangene Corp |
anticorpos contra clostridium difficile
|